Elmar Wolf is a tumor biologist whose research focuses on oncogenic transcription factors and strategies to therapeutically target them. In collaboration with medicinal chemistry partners, he pursues the approach of directing tumorigenic proteins toward proteasomal degradation using PROTACs (proteolysis-targeting chimeras). These small molecules are not only powerful cell biological tools but also represent an entirely novel and unique therapeutic strategy. Elmar develops PROTACs within projects funded by the ERC (Starting, Consolidator, and Proof of Concept Grants), the German Cancer Aid (consortium project TACTIC), and the DFG (Collaborative Research Center 387).